Evaluation of HER2 Expression in Prostate Cancer among Mexican Patients.

IF 1.8 3区医学 Q3 ONCOLOGY

Oncology Pub Date : 2025-07-14 DOI:10.1159/000547372

Ignacio Antonio Tapia-Salas, Rita Dorantes-Heredia, Rodrigo Rafael Flores-Marinelarena, Regina Moreno-Lopez, Ruth Mariana Sánchez-Pichardo, Jose Ruiz-Morales

{"title":"Evaluation of HER2 Expression in Prostate Cancer among Mexican Patients.","authors":"Ignacio Antonio Tapia-Salas, Rita Dorantes-Heredia, Rodrigo Rafael Flores-Marinelarena, Regina Moreno-Lopez, Ruth Mariana Sánchez-Pichardo, Jose Ruiz-Morales","doi":"10.1159/000547372","DOIUrl":null,"url":null,"abstract":"Introduction: Prostate cancer is one of the main types of cancer in men; specifically, in Mexico there is an increasing trend in incidence in the last 2 decades. The lack of targeted therapy in this neoplasm compels us to find new biomarkers that could work as possible drug targets. HER2 is a protein in cell membrane that has been targeted with different types of antibodies in multiple neoplasms, such as breast or gastric cancer. In prostate cancer, there are few reports of HER2 expression; in one study, the incidence of HER2 in prostatic tissue was 15%, mainly with low expression of the protein; in another report that included a total of 2,525 patients, they reported up to 22.5% of HER2 expression, with HER2 1+ and 2+ being the most common report. There are no reports of HER2 expression in Mexican population.Methods: We identified patients diagnosed with prostate cancer through prostatectomy or transurethral resection of the prostate, between January 2017 and December 2021 in a private hospital in Mexico City, and then performed immunohistochemistry utilizing VENTANA® HER2 (4B5).Results: A total of 277 patients with prostate cancer were included and finally a total of 194 patients were analyzed, reporting an expression of 21.1% of patients, with expression of HER2 1+ in 20.1%, HER2+ 0.5%, and HER2 3+ in 0.5% of patients. We found an association between the presence of HER2 and the prognostic group according to Gleason score that the patients were allocated in.Conclusion: Our study shows that expression of HER2 in prostate cancer in Mexican population is similar to that reported in other countries and that this biomarker could be used as a prognostic factor. As well, the overexpression of this protein might be used as a targeted therapy since there is evidence of the use of drugs such as fam-trastuzumab deruxtecan in different types of tumors that have a low expression of HER2, adding a new possible therapeutic weapon in a tumor with limited therapeutic options.","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-8"},"PeriodicalIF":1.8000,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000547372","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Prostate cancer is one of the main types of cancer in men; specifically, in Mexico there is an increasing trend in incidence in the last 2 decades. The lack of targeted therapy in this neoplasm compels us to find new biomarkers that could work as possible drug targets. HER2 is a protein in cell membrane that has been targeted with different types of antibodies in multiple neoplasms, such as breast or gastric cancer. In prostate cancer, there are few reports of HER2 expression; in one study, the incidence of HER2 in prostatic tissue was 15%, mainly with low expression of the protein; in another report that included a total of 2,525 patients, they reported up to 22.5% of HER2 expression, with HER2 1+ and 2+ being the most common report. There are no reports of HER2 expression in Mexican population.

Methods: We identified patients diagnosed with prostate cancer through prostatectomy or transurethral resection of the prostate, between January 2017 and December 2021 in a private hospital in Mexico City, and then performed immunohistochemistry utilizing VENTANA® HER2 (4B5).

Results: A total of 277 patients with prostate cancer were included and finally a total of 194 patients were analyzed, reporting an expression of 21.1% of patients, with expression of HER2 1+ in 20.1%, HER2+ 0.5%, and HER2 3+ in 0.5% of patients. We found an association between the presence of HER2 and the prognostic group according to Gleason score that the patients were allocated in.

Conclusion: Our study shows that expression of HER2 in prostate cancer in Mexican population is similar to that reported in other countries and that this biomarker could be used as a prognostic factor. As well, the overexpression of this protein might be used as a targeted therapy since there is evidence of the use of drugs such as fam-trastuzumab deruxtecan in different types of tumors that have a low expression of HER2, adding a new possible therapeutic weapon in a tumor with limited therapeutic options.

查看原文本刊更多论文

墨西哥前列腺癌患者中HER2表达的评估

前列腺癌是男性癌症的主要类型之一，特别是在墨西哥，在过去二十年中发病率呈上升趋势。这种肿瘤缺乏靶向治疗，迫使我们寻找新的生物标志物，作为可能的药物靶点。HER2是细胞膜上的一种蛋白，在多种肿瘤（如乳腺癌或胃癌）中已被不同类型的抗体靶向。在前列腺癌中，HER2表达的报道很少；在一项研究中，HER2在前列腺组织中的发生率为15%，主要为低表达；在另一份包括2525名患者的报告中，他们报告了高达22.5%的HER2表达是HER2 1+和2+，这是最常见的报告。在墨西哥人群中没有HER2表达的报道。我们在2017年1月至2021年12月期间在墨西哥城一家私立医院通过前列腺切除术或经尿道前列腺切除术诊断为前列腺癌的患者，然后使用VENTANA®HER2 （4B5）进行免疫组化。共纳入277例前列腺癌患者，最终分析194例患者，报告表达率为21.1%的患者，其中HER2 1+表达率为20.1%，HER2+表达率为0.5%，HER2 3+表达率为0.5%。根据Gleason评分，我们发现HER2的存在与患者分配的预后组之间存在关联。我们的研究表明，HER2在墨西哥前列腺癌人群中的表达与其他国家的报道相似，并且这种生物标志物可以用作预后因素。此外，这种蛋白的过表达可能被用作一种靶向治疗，因为有证据表明，在HER2低表达的不同类型的肿瘤中使用药物如fama - trastuzumab deruxtecan，为治疗选择有限的肿瘤增加了一种新的可能的治疗武器。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncology 医学-肿瘤学

CiteScore

6.00

自引率

2.90%

发文量

审稿时长

6-12 weeks

期刊介绍： Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.